Second‐Line Therapy Following Osimertinib in Metastatic <scp> <i>EGFR</i> </scp> ‐Mutated Non‐Small‐Cell Lung Cancer at an Academic Medical Center

Michael Rafizadeh, Stephanie Bogdan, Jonathan Lee, Christine Garcia, Ashish Saxena, Kathy Zhou, Bobak Parang

Open source

DOI: 10.1002/cnr2.70693
Published: 2026-09
Container: Cancer Reports
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cnr2.70693,
  title = {Second‐Line Therapy Following Osimertinib in Metastatic
                    <scp>
                      <i>EGFR</i>
                    </scp>
                    ‐Mutated Non‐Small‐Cell Lung Cancer at an Academic Medical Center},
  author = {Michael Rafizadeh and Stephanie Bogdan and Jonathan Lee and Christine Garcia and Ashish Saxena and Kathy Zhou and Bobak Parang},
  year = {2026},
  journal = {Cancer Reports},
  doi = {10.1002/cnr2.70693},
  url = {https://doi.org/10.1002/cnr2.70693}
}

RIS

TY  - JOUR
TI  - Second‐Line Therapy Following Osimertinib in Metastatic
                    <scp>
                      <i>EGFR</i>
                    </scp>
                    ‐Mutated Non‐Small‐Cell Lung Cancer at an Academic Medical Center
AU  - Michael Rafizadeh
AU  - Stephanie Bogdan
AU  - Jonathan Lee
AU  - Christine Garcia
AU  - Ashish Saxena
AU  - Kathy Zhou
AU  - Bobak Parang
PY  - 2026
JO  - Cancer Reports
DO  - 10.1002/cnr2.70693
UR  - https://doi.org/10.1002/cnr2.70693
ER  -

APA

Rafizadeh, M., Bogdan, S., Lee, J., Garcia, C., Saxena, A., Zhou, K., & Parang, B. (2026). Second‐Line Therapy Following Osimertinib in Metastatic <scp> <i>EGFR</i> </scp> ‐Mutated Non‐Small‐Cell Lung Cancer at an Academic Medical Center. Cancer Reports. https://doi.org/10.1002/cnr2.70693

Source records

crossref · retrieved 2026-09-25T00:54:23.038Z